Bio-complexity: Challenging reductionism

Handbook of Systems and Complexity in Health

Volumn , Issue , 2013, Pages 193-208

  Heng, Henry H Q ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85013709333     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-4998-0_12     Document Type: Chapter

References (44)

1. Evans JP, Meslin EM, Marteau TM, Caulfield T. Deflating the genomic bubble. Science. 2011;331:861-2.
2. Heng HH. The conflict between complex systems and reductionism. JAMA. 2008;300:1580-1.
3. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff Jr.DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm Jr.RH, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59.
4. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse III JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff Jr.DC, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-74.
5. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff Jr.DC, Grimm Jr.RH, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85.
6. The International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748-52.
7. Paynter NP, Chasman DI, Paré G, Buring JE, Cook NR, Miletich JP, Ridker PM. Association between a literature-based genetic risk score and cardiovascular events in women. JAMA. 2010;303:631-7.
8. Heng HH. Missing heritability and stochastic genome alterations. Nat Rev Genet. 2010;11:813.
9. Heng HH, Stevens JB, Bremer SW, Ye KJ, Liu G, Ye CJ. The evolutionary mechanism of cancer. J Cell Biochem. 2010;220:538-47.
10. Heng HH, Liu G, Stevens JB, Bremer SW, Ye KJ, Abdallah BY, Horne SD, Ye CJ. Decoding the genome (rather than sequencing linear DNA): the next phase of genomic research. Genomics. 2011;98:242-52.
11. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and a $440 billion question. J Natl Cancer Inst. 2009;101:1044-8.
12. Mittra I. The disconnection between tumor response and survival. Nat Clin Pract Oncol. 2007;4:203.
13. Heng HH, Liu G, Stevens JB, Bremer SW, Ye KJ, Ye CJ. Genetic and epigenetic heterogeneity in cancer: the ultimate challenge for drug therapy. Curr Drug Targets. 2010;11:1304-16.
14. Maley CC, Reid BJ, Forrest S. Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity. Cancer Epidemiol Biomarkers Prev. 2004;13:1375-84.
15. Heng HH, Bremer SW, Stevens JB, Liu G, Ye CJ. Evolutionary mechanisms and diversity in cancer. Adv Cancer Res. 2011;112:217-53.
16. Collins FS, Barker AD. Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci Am. 2007;296:50-7.
17. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789-99.
18. Heng HH. Cancer genome sequencing: The challenges ahead. BioEssays. 2007;29:783-94.
19. Sturmberg JP. Systems and complexity thinking in general practice: part 1 - clinical application. Aust Fam Physician. 2007;36:170-3.
20. Heng HH. The genome-centric concept: resynthesis of evolutionary theory. Bioessays. 2009;31:512-25.
21. Rancati G, Pavelka N, Fleharty B, Noll A, Trimble R, Walton K, Perera A, Staehling-Hampton K, Seidel CW, Li R. Aneuploidy underlies rapid adaptive evolution of yeast cells deprived of a conserved cytokinesis motor. Cell. 2008;135:789-91.
22. Heng HH, Chamberlain JW, Shi XM, Spyropoulos B, Tsui LC, Moens PB. Regulation of meiotic chromatin loop size by chromosomal position. Proc Natl Acad Sci U S A. 1996;93:2795-800.
23. Heng HH, Goetze S, Ye CJ, Liu G, Stevens JB, Bremer SW, Wykes SM, Bode J, Krawetz SA. Chromatin loops are selectively anchored using scaffold/matrixattachment regions. J Cell Sci. 2004;117:999-1008.
24. Heng HH, Bremer SW, Stevens JB, Ye KJ, Liu G, Ye CJ. Genetic and epigenetic heterogeneity in cancer: a genomecentric perspective. J Cell Physiol. 2009;220:538-47.
25. Davidoff F. Heterogeneity is not always noise lessons from improvement. JAMA. 2009;302:2580-6.
26. Heppner GH. Tumor heterogeneity. Cancer Res. 1984; 44:2259-65.
27. Lander ES. Initial impact of the sequencing of the human genome. Nature. 2011; 470:187-97.
28. Ye CJ, Liu G, Bremer SW, Heng HH. The dynamics of cancer chromosomes and genomes. Cytogenet Genome Res. 2007; 118:237-46.
29. Heng HH. 4D-Genomics: genome dynamics and constraint in evolution. Springer (in press).
30. Horne SD, Stevens JB, Abdallah BY, Liu G, Bremer SW, Ye CJ, Heng HH. Why imatinib remains an exception of cancer research. J Cell Physiol 2012; doi:10.1002/jcp.24233.
31. Heng HH. Elimination of altered karyotypes by sexual reproduction preserves species identity. Genome. 2007; 50: 517-524.
32. Wilkins and Holliday. The evolution of meiosis from mitosis. Genetics. 2009; 181: 2-12.
33. Gorelick R and Carpione. J. Origin and maintenance of sex: the evolutionary joys of self sex. Biol. J. Soc. 2009; 98: 707-728.
34. Gorelick R and Heng HH. Sex reduces genetic variation: a multidisciplinary review. 2011; Evolution. 64: 1088-1098.
35. Heng HH. Preface: Back to the future. Cytogenet Genome Res 2012; (in press).
36. Stevens JB, Abdallah BY, Liu G, Ye CJ, Horne SD, Wang G, Savasan S, Shekhar M, Krawetz SA, Huttemann M, Taiinsky MA, Wu GS, Xie Y, Zhang K, and Heng HH. Diverse system stresses: common mechanisms of chromosome fragmentation. Cell Death and Disease. 2011; 2:e178. Doi:10.1038/cddis.2011.60
37. Heng HH, Stevens JB, Liu G, Bremer SW, Ye KJ, Reddy PV, Wu GS, Wang YA, Tainsky MA, Ye CJ. Stochastic cancer progression driven by non-clonal chromosome aberrations. J Cell Physiol. 2006; 208: 461-472.
38. Stevens JB, Abdallah BY, Liu G, Horne SD, Bremer SB, Ye KJ, Kurkinen M, Ye CJ, Heng HH. Heterogeneity of cell death. Cytogenet Genome Res 2012; (in press).
39. Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, Antosiewicz-Bourget J, O'Malley R, Castanon R, Klugman S, Downes M, Yu R, Stewart R, Ren B, Thomson JA, Evans RM, Ecker JR. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature. 2011 Mar 3;471(7336):68-73.
40. Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, et al. 2009 Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient. PLoS Med 2009; 6: e1000029.
41. Heng HH, Stevens J, Lawrenson L, Liu G, Ye KJ, Bremer, S and Ye, CJ. Patterns of genome dynamics and cancer evolution. Cellular Oncology 2008; 30:513-4.
42. Ye CJ, Stevens JB, Liu G, Bremer SW, Jaiswal AS, Ye KJ, Lin MF, Lawrenson L, Lancaster WD, Kurkinen M, Liao JD, Gairola CG, Shekhar MP, Narayan S, Miller FR, Heng HH. Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. J Cell Physiol. 2009; 219: 288-300.
43. Nesse RM. Ten questions for evolutionary studies of diseases vulnerability. 2011; Evolutionary Applications 4:264-277, 2011
44. H. Gilbert Welch, Lisa Schwartz, and Steve Woloshin. 2011. Overdiagnosed: making people sick in the pursuit of health. Beacon Press.